Mobile

A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5μg compared with two inhalations of Seretide 25/250μ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001724-20

A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5μg compared with two inhalations of Seretide 25/250μg, two inhalations of Ventoline 100μg, and placebo, delivered by pressurised metered dose inhalers, in patients with chronic obstructive pulmonary disease (COPD)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate efficacy i.e. to study the bronchodilatating effect within the first 180 minutes after two inhalations of Symbicort 160/4.5μg compared with two inhalations of Seretide 25/250μg, two inhalations of Ventoline 100μg, and placebo, delivered by pressurised metered dose inhalers, in patients with chronic obstructive pulmonary disease (COPD).

Critère d'inclusion

  • This is an application for a phase III study to be conducted in COPD patients

Liens